Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.


Journal

The neuroradiology journal
ISSN: 2385-1996
Titre abrégé: Neuroradiol J
Pays: United States
ID NLM: 101295103

Informations de publication

Date de publication:
Apr 2020
Historique:
pubmed: 21 1 2020
medline: 17 12 2020
entrez: 21 1 2020
Statut: ppublish

Résumé

To investigate multivariable analyses for noninvasive association of the isocitrate dehydrogenase (IDH) mutational status in grade II and III gliomas including evaluation of T2 mapping-sequences. Magnetic resonance imaging (MRI) examinations with histopathologically proven World Health Organization grade II and III gliomas were retrospectively enrolled. Multivariate receiver operating characteristics (ROC) analyses to associate IDH mutational status were performed containing quantitative T2 mapping analyses and qualitative characteristics (sex, age, localization, heterogeneity, oedema, necrosis and diameter). Relaxation times were calculated pixelwise by means of standardized ROI analyses. Interobserver variability also was tested. Out of 32 patients (mean age: 50.7 years; range: 32-83), nine had grade II gliomas and 24 grade III, while 59.5% showed a positive IDH mutated state (IDHm) and 40.5% were wildtype (IDHw). Multivariable ROC analyses were calculated for relaxation time and range, localization and age with a cumulative 0.955 area under the curve (AUC) ( This is the first study evaluating quantitative T2 mapping sequences for association of the IDH mutational status in grade II and III gliomas demonstrating an association between relaxation time and mutational status. Analyses of T2 mapping relaxation times may even be suitable for predicting the correct IDH mutational state. Prognostic accuracy increases significantly in predicting the correct mutational state when combing T2 relaxation time characteristics and the qualitative MRI features age and localization.

Identifiants

pubmed: 31957551
doi: 10.1177/1971400919890099
pmc: PMC7140300
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

160-168

Références

Radiology. 2017 Aug;284(2):316-331
pubmed: 28723281
Eur J Neurol. 2015 Feb;22(2):348-54
pubmed: 25318355
Neuroradiol J. 2013 Oct;26(5):531-41
pubmed: 24199813
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Eur Radiol. 2008 Aug;18(8):1727-35
pubmed: 18389246
AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1081-8
pubmed: 11415902
AJNR Am J Neuroradiol. 2019 Mar;40(3):426-432
pubmed: 30705071
J Neurooncol. 2015 Jan;121(1):141-50
pubmed: 25205290
Neuroradiol J. 2017 Feb;30(1):36-47
pubmed: 27864578
Br J Radiol. 2005 Mar;78(927):230-5
pubmed: 15730987
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1306-1311
pubmed: 28293705
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286
Brain Tumor Pathol. 2015 Apr;32(2):99-104
pubmed: 25537428
PLoS One. 2013 Sep 16;8(9):e74795
pubmed: 24066153
J Neurooncol. 2017 May;133(1):37-45
pubmed: 28434111
Eur Radiol. 2019 Feb;29(2):745-758
pubmed: 30003316
J Neurooncol. 2018 Sep;139(3):633-642
pubmed: 29860714
Oncol Lett. 2014 Jun;7(6):1895-1902
pubmed: 24932255
Br J Radiol. 2018 Apr;91(1084):20170803
pubmed: 29271237
Neuroradiol J. 2015 Apr;28(2):106-11
pubmed: 25923676
Acta Neurochir (Wien). 2017 Mar;159(3):403-418
pubmed: 28093610
J Neurosurg. 2011 Nov;115(5):948-65
pubmed: 22043865
AJNR Am J Neuroradiol. 2018 Jan;39(1):37-42
pubmed: 29122763
AJR Am J Roentgenol. 2018 Mar;210(3):621-628
pubmed: 29261348
Acta Neuropathol. 2010 Nov;120(5):567-84
pubmed: 20714900
Radiology. 2011 Dec;261(3):882-90
pubmed: 21969667
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acta Neuropathol. 2010 Dec;120(6):719-29
pubmed: 21080178
Neuro Oncol. 2013 Oct;15(10):1395-404
pubmed: 23925453
Neuro Oncol. 2017 Jan;19(1):109-117
pubmed: 27353503

Auteurs

Maike Kern (M)

Department of Neuroradiology, Charite University Hospital Berlin, Germany.
Department of Radiology, Charite University Hospital Berlin, Germany.

Timo A Auer (TA)

Department of Radiology, Charite University Hospital Berlin, Germany.

Uli Fehrenbach (U)

Department of Radiology, Charite University Hospital Berlin, Germany.

Yasemin Tanyildizi (Y)

Department of Neuroradiology, University Medicial Center Mainz, Germany.

Thomas Picht (T)

Department of Neurosurgery, Charite University Hospital Berlin, Germany *These authors contributed equally to this work.

Martin Misch (M)

Department of Neurosurgery, Charite University Hospital Berlin, Germany *These authors contributed equally to this work.

Edzard Wiener (E)

Department of Neuroradiology, Charite University Hospital Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH